Articles related to FDA

The FDA’s recent decision allows Fulcrum Therapeutics to continue its Phase 1b trial of FTX-6058, an oral therapy for SCD. The trial aims to explore the drug’s potential in increasing fetal hemoglobin levels, offering a new avenue for treatment.

Xdemvy, backed by robust clinical trials, offers a new, targeted treatment option for Demodex blepharitis. The FDA-approved solution is expected to be available by the end of August 2023.

GE HealthCare’s Portrait Mobile, recently cleared by the FDA, offers a novel approach to patient monitoring, allowing continuous oversight without confining patients to their beds. Explore how this innovative technology could redefine hospital care practices.

The recent FDA approval of brexpiprazole for Alzheimer’s dementia patients has ignited concerns among healthcare professionals. Physicians are urged to carefully consider the drug’s minimal efficacy and increased mortality risk in their treatment decisions.

The FDA’s approval of Daxxify offers a promising new treatment for cervical dystonia. Explore the comprehensive clinical data that supports this peptide-formulated neuromodulator’s efficacy and safety profile.

The FDA’s recent approval of Akeega, a combination therapy for BRCA-mutated mCRPC, marks a significant advancement in targeted treatment. This approval, based on the MAGNITUDE study, offers a new therapeutic option for patients, supported by robust clinical data.